Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9404995 | 0.91 | LMNA (0.47) | LMNATP53MEN1MAPTKMT2A | |
| SCHEMBL27771387 | 0.88 | LMNA (0.54) | LMNATP53MEN1MAPTKMT2A | |
| SCHEMBL27941740 | 0.85 | TDP1 (0.49) | LMNAMEN1MAPTKMT2ACYP1A2 | |
| SCHEMBL657614 | 0.85 | ALDH1A1 (0.59) | LMNAMEN1MAPTKMT2AF2 | |
| SCHEMBL27679166 | 0.85 | ALDH1A1 (0.59) | LMNAMEN1MAPTKMT2AF2 | |
| SCHEMBL20299326 | 0.84 | TSHR (0.52) | LMNATP53F2ALDH1A1TSHR | |
| SCHEMBL27612334 | 0.84 | CHRNB2 (0.51) | LMNAMEN1MAPTKMT2AF2 | |
| SCHEMBL7671999 | 0.83 | TSHR (0.55) | LMNATP53MEN1MAPTKMT2A | |
| SCHEMBL30283493 | 0.82 | ALDH1A1 (0.61) | LMNAMEN1MAPTKMT2AGAA | |
| SCHEMBL829966 | 0.82 | LMNA (0.59) | LMNAMEN1MAPTKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| EP-1735298-A1 | PIPERIDINE DERIVATES FOR THE TREATMENT OF CHEMOKINES MEDIARED DISEASE | AstraZeneca AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097775-A1 | PIPERIDINE DERIVATES FOR THE TREATMENT OF CHEMOKINES MEDIARED DISEASE | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | CCR3, CCR1, CCR4 | LMNA 4019/4885TP53 3499/4885MEN1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.